早期子宫内膜癌中淋巴血管间隙浸润程度跨分子分型的预后意义:一项大型回顾性分析
该回顾性研究纳入2374例I-II期子宫内膜癌患者,按WHO标准将LVSI分为阴性、局灶性和广泛性,并结合分子分型分析。结果显示局灶性LVSI不影响无病生存,而广泛性LVSI与侵袭性临床病理特征相关,并在NSMP-LR、MMRd和p53abn亚组中独立预测更差的无病生存,使复发风险增加约2.5-2.8倍。
要点
- 局灶性LVSI在各分子亚型中均不影响无病生存。
- 广泛性LVSI与更大肿瘤、深肌层浸润、宫颈受累及非子宫内膜样组织学相关。
- 广泛性LVSI在NSMP-LR、MMRd和p53abn亚组中独立预测更差的无病生存。
核心结论
- 在I-II期子宫内膜癌中,局灶性LVSI不恶化肿瘤学结局,而广泛性LVSI与侵袭性特征相关并独立预测部分分子亚组更差的无病生存。
研究设计与样本
- 回顾性纳入2374例接受完整初次手术分期的I-II期子宫内膜癌患者,按WHO标准分为LVSI阴性、局灶性和广泛性,并采用下一代测序和免疫组化进行分子分型。
主要发现
- LVSI阴性占73.7%(n=1750),局灶性占11.5%(n=273),广泛性占14.8%(n=351)。
- 任何LVSI与更大肿瘤尺寸、更深肌层浸润和宫颈受累相关(均p<0.001)。
- 广泛性LVSI还与未子宫内膜样组织学、3级病变、ER<10%以及p53abn和NSMP-HR肿瘤更高患病率相关(均p<0.001)。
- 多变量Cox分析显示,广泛性LVSI在NSMP-LR、MMRd和p53abn亚组中独立预测更差的无病生存,而局灶性LVSI不影响无病生存。
- 在POLEmut或NSMP-HR肿瘤中未发现显著生存关联,但广泛性LVSI在所有分子类别中均与更高复发风险一致相关(RR 2.5-2.8)。
临床怎么用
- 对I-II期子宫内膜癌应常规评估LVSI程度并按WHO标准区分局灶性与广泛性。
- 广泛性LVSI可结合分子分型用于识别NSMP-LR、MMRd和p53abn亚组中高复发风险患者。
局限性
- 回顾性研究设计可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognostic role of lymphovascular space invasion (LVSI) in endometrial cancer (EC) remains poorly defined across molecular subgroups. We evaluated the impact of LVSI extent in a large cohort of stage I-II EC classified according to molecular profiling. METHODS: Patients with stage I-II EC who underwent complete primary surgical staging were retrospectively included. According to WHO criteria, cases were classified as LVSI-negative, focal LVSI, or substantial LVSI. Molecular classification was performed using next-generation sequencing and immunohistochemistry, identifying the following groups: POLE-mutated (POLEmut), mismatch repair-deficient (MMRd), p53-abnormal (p53abn), low-risk no specific molecular profile (NSMP-LR), and high-risk NSMP (NSMP-HR). RESULTS: Among 2374 patients, LVSI was absent in 73.7% (n = 1750), focal in 11.5% (n = 273), and substantial in 14.8% (n = 351). Any LVSI was associated with larger tumor size, deeper myometrial invasion, and cervical involvement (all p < 0.001). Substantial LVSI was additionally associated with non-endometrioid histology, grade 3 disease, ER < 10%, and higher prevalence of p53abn and NSMP-HR tumors (all p < 0.001). On multivariable Cox analysis, substantial LVSI independently predicted worse disease-free survival in NSMP-LR, MMRd, and p53abn subgroups, whereas focal LVSI did not affect disease-free survival. No significant survival association was found in POLEmut or NSMP-HR tumors. Nevertheless, substantial LVSI was consistently associated with higher recurrence risk across all molecular classes (RR 2.5-2.8). CONCLUSIONS: In stage I-II EC, focal LVSI does not worsen oncologic outcomes across molecular subgroups. In contrast, substantial LVSI associates with aggressive clinicopathologic features and independently predicts poorer disease-free survival in selected molecular groups, increasing recurrence risk by approximately 2.5-2.8-fold.
引用
- Capasso I, Perrone E, Mancusi RL, et al. Prognostic significance of lymphovascular space invasion extent across molecular classes in early-stage endometrial cancer: A large retrospective analysis. Eur J Cancer. 2026. PMID: 42224884. doi:10.1016/j.ejca.2026.116846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。